Barinthus Biotherapeutics's stock is projected to advance by 208.37% from the previous closing price if it reaches the average target of $7.00 by the year's end, as reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $12.00 and a low-end estimate of $3.00.

$7.00

208.37% Upside

Outperform

Barinthus Biotherapeutics Fair Value Forecast for 2023 - 2025 - 2030

In the last three years, Barinthus Biotherapeutics's Price has grown by 100.00%, rising from $0.00 to $0.00. For the next year, analysts predict that Fair Value will reach $0.00 – an increase of 100.00%. Over the next six years, experts believe that Barinthus Biotherapeutics's Fair Value will grow at a rate of 100.00%.

2025 Fair Value Forecast

$0.00

2026 Fair Value Forecast

$0.00

2027 Fair Value Forecast

$0.00

2028 Fair Value Forecast

$0.00

2029 Fair Value Forecast

$0.00

2030 Fair Value Forecast

$0.00

Barinthus Biotherapeutics Revenue Forecast for 2023 - 2025 - 2030

In the last two years, Barinthus Biotherapeutics's Revenue has grown by 827.39%, rising from $4.82M to $44.70M. For the next year, analysts predict that Revenue will reach $266.17M – an increase of 495.46%. Over the next eight years, experts believe that Barinthus Biotherapeutics's Revenue will grow at a rate of 4772.78%.

2023 Rev Forecast

$0.27B

2024 Rev Forecast

$1.60B

2025 Rev Forecast

$0.18B

2026 Rev Forecast

$0.55B

2027 Rev Forecast

$1.72B

2028 Rev Forecast

$5.42B

2029 Rev Forecast

$1.75B

2030 Rev Forecast

$2.18B

Barinthus Biotherapeutics Dividend per Share Forecast for 2023 - 2025 - 2030

Barinthus Biotherapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030

Barinthus Biotherapeutics EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, Barinthus Biotherapeutics's EBITDA has decreased by 89.86%, going from $-16.56M to $-1.68M. In the next year, analysts believe that EBITDA will reach $-27.44M – an increase of 1533.36%. For the next eight years, the forecast is forEBITDA to grow by 130632.76%.

2023 EBITDA Forecast

$-27440504.00

2024 EBITDA Forecast

$-226516787.10

2025 EBITDA Forecast

$-1848369432.20

2026 EBITDA Forecast

$-187794334.31

2027 EBITDA Forecast

$-631370811.77

2028 EBITDA Forecast

$-2159793272.89

2029 EBITDA Forecast

$-7510465127.14

2030 EBITDA Forecast

$-2196310352.01

Barinthus Biotherapeutics EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Barinthus Biotherapeutics's EBIT has decreased from $-16.77M to $-2.80M – a 83.30% drop. In the coming year, analysts are expecting an increase in EBIT, predicting it will reach $-27.86M – an increase of 894.99%. Over the next eight years, experts anticipate that EBIT growth for Barinthus Biotherapeutics will be 20747.96%.

2023 EBIT Forecast

$-27859626.67

2024 EBIT Forecast

$-141421965.54

2025 EBIT Forecast

$-708000786.08

2026 EBIT Forecast

$-117339330.28

2027 EBIT Forecast

$-251516854.45

2028 EBIT Forecast

$-561720974.95

2029 EBIT Forecast

$-1300964502.01

2030 EBIT Forecast

$-583742772.05

Barinthus Biotherapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, Barinthus Biotherapeutics's EPS has grown by 100.00%, rising from $-1.67 to $0.00. For the next year, analysts predict that EPS will reach $-0.00 – an increase of 100.00%. Over the next six years, experts believe that Barinthus Biotherapeutics's EPS will grow at a rate of 100.00%.

2025 EPS Forecast

$-0.00

2026 EPS Forecast

$-0.00

2027 EPS Forecast

$-0.00

2028 EPS Forecast

$-0.00

2029 EPS Forecast

$-0.00

2030 EPS Forecast

$-0.00